[Substance P and anticancer drug-induced emesis].
BACKGROUND
Cytotoxic drug-induced emesis is the side effect most feared by cancer patients. The Acute emesis has become well controlled by the emergence appearance of 5-HT3 receptor antagonist, but control of delayed emesis (DE) is insufficient. The mechanism of DE is different from acute emesis,and the existence of a mediator different from serotonin is contemplated. There were some reports suggesting the role of substance P (SP) and its receptor, neurokinin receptor 1 (NK 1), in the development of emesis.


OBJECTIVE
We investigated the relationship between DE and SP in patients treated with anticancer agents.


METHODS
Digestive cancer and breast cancer patients, who were administered cytotoxic agents, were the objects of this study. We measured plasma levels of SP for 20 cases on the day before administration of anticancer agents and for five days after administration.


RESULTS
Plasma levels of SP increased significantly on the first and third days after administration. In the patient who experienced DE, the difference in plasma levels on the day before and the first day after chemotherapy was higher than that of who never experienced.


CONCLUSIONS
The plasma levels of SP were transiently increased by chemotherapy. The difference in plasma levels between the day before and the first day after chemotherapy is important.
Yamada
Takeshi
T
Dept. of Surgery,Chiba Hokusoh Hospital.
Tanaka
Noritake
N
Yokoi
Kimiyoshi
K
Ishikawa
Noriyuki
N
Seya
Tomoko
T
Horiba
Kouji
K
Kanazawa
Yoshikazu
Y
Shirakawa
Takashi
T
Ohkawa
Keiichi
K
Kudoh
Hidenori
H
Koizumi
Michihiro
M
Yoshioka
Masato
M
Tajiri
Takashi
T
D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy; D004067:Digestive System Neoplasms / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000097:blood* / Q000139:chemically induced; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D058831:Serotonin 5-HT3 Receptor Antagonists; D013373:Substance P / Q000097:blood*; D014840:Vomiting, Anticipatory / Q000097:blood* / Q000139:chemically induced
D000970:Antineoplastic Agents; D018040:Receptors, Neurokinin-1; D058831:Serotonin 5-HT3 Receptor Antagonists; D013373:Substance P